Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,072 public trials 579 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Active, Not Recruiting

Lenalidomide Maintenance in Plasma Cell Myeloma

NCT02538198

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
  • Memorial Sloan Kettering Westchester Harrison, New York, United States
View Trial Details
Active, Not Recruiting

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

NCT04108195

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
  • University of California San Francisco San Francisco, California, United States
  • The Blavatnik Family Chelsea Medical Center at Mount Sinai New York, United States
View all 24 locations
View Trial Details
Active, Not Recruiting

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

NCT05431608

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited protocol activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack (Limited protocol activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Cancer Center-Scottsdale Phoenix, Arizona, United States
  • Stanford University Medical Center Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 88 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Princess Margaret Hospital Toronto, Ontario, Canada
  • Jewish General Hospital Montreal, Quebec, Canada
  • Seoul National University Hospital Seoul, South Korea
  • Asan Medical Center Seoul, South Korea
View all 15 locations
View Trial Details
Active, Not Recruiting

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Emory University Atlanta, Georgia, United States
View all 31 locations
View Trial Details
Active, Not Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSF San Francisco, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • University of Miami Health System Miami, Florida, United States
  • AdventHealth Cancer Institute Orlando, Florida, United States
View all 136 locations
View Trial Details
Active, Not Recruiting

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
View Trial Details
Active, Not Recruiting

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT04133636

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University Of California San Diego San Diego, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 47 locations
View Trial Details

Related conditions